SciTransfer
Expertise area

Regenerative medicine and tissue engineering

5 European H2020 organizations list this as part of their work.

Top organizations

Most active in this area

  • UNIVERSITATSSPITAL BASEL

    Swiss university hospital contributing clinical and translational expertise in neuroscience, cancer biology, and regenerative medicine to large EU research consortia.

    BIO-CHIP (cartilage grafts), EpiCrest2Reg (disc regeneration), cmRNAbone (bone regeneration via 3D-printed gene therapy), and ELASTISLET (cell therapy for diabetes) demonstrate breadth in musculoskeletal and soft tissue repair.

    CH15 projects
  • HELSE BERGEN HF

    Major Norwegian university hospital contributing clinical cohorts, biobanks, and trial infrastructure to European immunology, respiratory, and personalized medicine research.

    SC0806 addressed spinal cord injury with surgical implantation of biomaterials; MAXIBONE works on personalized maxillofacial bone regeneration using mesenchymal stem cells and 3D-printed biomaterials.

    NO14 projects
  • MANCHESTER UNIVERSITY NHS FOUNDATION TRUST

    Major NHS teaching hospital trust providing clinical patient access, rare disease expertise, and pregnancy safety data to European health research consortia.

    TETRA developed autologous stem cell-seeded tissue-engineered trachea, their largest directly-funded project at EUR 483,512.

    UK9 projects
  • CHILDREN'S HOSPITAL CORPORATION

    Major US pediatric research hospital contributing clinical expertise in pain medicine, neurology, immunology, and regenerative medicine to European consortia.

    DIRECT Therapies (encapsulated cell transplants for diabetes) and ReSurface (articular cartilage repair) represent a newer direction in regenerative approaches.

    US9 projects
  • CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE

    Italian research consortium specializing in paediatric pharmacology, clinical trial infrastructure, and drug development for children and rare diseases.

    Participated in AMELIE (anchored muscle cells for faecal incontinence), their largest funded project at EUR 797,887, signalling a move into cell-based therapies.

    IT6 projects